Abstract: A pharmaceutical composition for preparation of an orally administered liquid solution containing a therapeutically sufficient dose of dissolved balsalazide. The composition further comprises three artificial sweeteners comprising sucralose, acesulfame potassium and ammonium glycyrrhizinate that unexpectedly mitigate the bitter attributes of the orally administered liquid balsalazide solution that would otherwise render the solution unpalatable. More particularly, the present disclosure relates to a composition of the three artificial sweeteners and a therapeutically sufficient dose of balsalazide for the treatment of bowel disorders such as ulcerative colitis. Unit dose sachets of balsalazide disodium 750 mg and 2,250 mg of powder to oral solution are also disclosed.

Abstract: A pharmaceutical composition for preparation of an orally administered liquid solution containing a therapeutically sufficient dose of dissolved balsalazide. The composition further comprises three artificial sweeteners comprising sucralose, acesulfame potassium and ammonium glycyrrhizinate that unexpectedly mitigate the bitter attributes of the orally administered liquid balsalazide solution that would otherwise render the solution unpalatable. More particularly, the present disclosure relates to a composition of the three artificial sweeteners and a therapeutically sufficient dose of balsalazide for the treatment of bowel disorders such as ulcerative colitis. Unit dose sachets of balsalazide disodium 750 mg and 2,250 mg of powder to oral solution are also disclosed.

Abstract: The present invention is a novel oral formulation for the administration of either celecoxib or allopurinol which provides a useful shelf life and is easy to re-suspend.

Abstract: Administration of an NSAID with at least one dual inhibitor of mPGES-1 and NF-?B plus at least one zwitterionic phospholipid rests in a lessening of side effects and the ability to administer smaller doses of an NSAID without loss of effectiveness.

Abstract: The present invention relates to the use of triterpenes of the formula (I): which are inhibitors of nuclear factor kappa B (NF-?B for use in the treatment of inflammatory diseases and for cancers susceptible to an NF-?B inhibitor. The present invention also relates to compounds and methods useful to inhibit cell proliferation and for the induction of apoptosis.

Abstract: The present invention relates to the use of triterpenes of the formula (I): which are inhibitors of nuclear factor kappa B (NF-KB for use in the treatment of inflammatory diseases and for cancers susceptible to an NF-KB inhibitor. The present invention also relates to compounds and methods useful to inhibit cell proliferation and for the induction of apoptosis.

Abstract: The present invention relates to the use of certain novel compositions from wax myrtle (Morella cerifera) which are inhibitors of nuclear factor kappa B (NF-kB), oxidative stress (activation of Nerf2) and the activity of the endothelin receptor. In particular, it relates to useful enriched fractions and pharmaceutical compositions from wax myrtle for use in the treatment of cardiovascular and inflammatory diseases and for cancers susceptible to an inhibitor of oxidative stress (activation of Nerf2), NF-kB inhibitor and an endothelin receptor inhibitor. The present invention also relates to compositions from wax myrtle useful to inhibit cell proliferation and for the induction of apoptosis.

Abstract: The present invention relates to the use of certain novel compositions from clary sage (Salvia sclarea) which are inhibitors of nuclear factor kappa B (NF-?B), oxidative stress (activation of Nerf2) and the activity of the endothelin receptor. In particular, it relates to useful enriched fractions and pharmaceutical compositions from clary sage for use in the treatment of cardiovascular and inflammatory diseases and for cancers susceptible to an inhibitor of oxidative stress (activation of Nerf2), NF-?B inhibitor and an endothelin receptor inhibitor. The present invention also relates to compositions from clary sage useful to inhibit cell proliferation and for the induction of apoptosis.

Abstract: The present invention relates to the use of certain novel myriceric acid derivatives of the formula: which are inhibitors of nuclear factor kappa B (NF-?B) and inhibit the activity of the endothelin receptor for use in the treatment of cardiovascular and inflammatory diseases and for cancers susceptible to an NF-?B inhibitor and an endothelin receptor inhibitor. The present invention also relates to compounds and methods useful to inhibit cell proliferation and for the induction of apoptosis.

Abstract: The invention features a method for inhibiting or reducing the deleterious effects of tobacco smoking including increased incidence of cancers, cardiovascular diseases, various lung disorders and the oxidative effects. The method includes the incorporation of an effective amount of a compound or a standardized plant extract that is that comprises an inhibitor of NF-?B into tobacco or a tobacco product. In particular, it relates to useful NF-?B inhibitor diterpenes and compositions containing them for incorporation into tobacco or a tobacco product.

Abstract: The present invention relates to the use of certain novel myriceric acid derivatives of the formula: which are inhibitors of nuclear factor kappa B (NF-?B) and inhibit the activity of the endothelin receptor for use in the treatment of cardiovascular and inflammatory diseases and for cancers susceptible to an NF-?B inhibitor and an endothelin receptor inhibitor. The present invention also relates to compounds and methods useful to inhibit cell proliferation and for the induction of apoptosis.

Abstract: The present invention relates to useful diterpenes and pharmaceutical compositions containing them of the formula: for use in the treatment of cardiovascular and inflammatory diseases and for cancers susceptible to an NF-?B inhibitor and an endothelin receptor inhibitor. The present invention also relates to compounds and methods useful to inhibit cell proliferation and for the induction of apoptosis.

Abstract: The invention relates to a method for treating cancer including administering to a mammal therapeutically effective amounts of an anti-neoplastic agent and a PDE4 inhibitor, treatment combinations containing the same as well as a method for attenuating unwanted cancer treatment side effects including myelosuppression and mucositis.